An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines

被引:18
作者
Smith, JA
Brown, J
Martin, MC
Ramondetta, LM
Wolf, JK
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Div Surg, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Dept Gynecol Med Oncol, Houston, TX 77030 USA
关键词
gemcitabine; cisplatin; endometrial carcinoma;
D O I
10.1016/j.ygyno.2003.09.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To determine the cytotoxic activity of gemcitabine on a panel of endometrial cancer cell lines and to determine if the addition of platinum agents enhanced this activity. Methods. A panel of four endometrial carcinoma cell lines was treated with variable concentrations of gemcitabine, gemcitabine and cisplatin, or gemcitabine and carboplatin. 3-(4,5-Cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays were performed to determine the IC50. Results. Each cell line evaluated revealed a dose-dependent decrease in cell growth for gemcitabine alone and in combination with platinum agents. The IC50 of gemcitabine with cisplatin was significantly lower than that of gemcitabine alone for all cell lines, including the platinum-resistant line. Conclusion. Gemcitabine exerts in vitro cytotoxicity on endometrial cancer cell lines, and the combination of gemcitabine and cisplatin is superior to gemcitabine alone. This may represent a promising option for treatment of endometrial cancer. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:314 / 319
页数:6
相关论文
共 18 条
[1]   A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study [J].
Ball, HG ;
Blessing, JA ;
Lentz, SS ;
Mutch, DG .
GYNECOLOGIC ONCOLOGY, 1996, 62 (02) :278-281
[2]   DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin [J].
Crul, M ;
van Waardenburg, RCAM ;
Bocxe, S ;
van Eijndhoven, MAJ ;
Pluim, D ;
Beijnen, JH ;
Schellens, JHM .
BIOCHEMICAL PHARMACOLOGY, 2003, 65 (02) :275-282
[3]  
Fiorica JV, 2002, ONCOLOGIST, V7, P36
[4]  
FLAMING G, 2000, P AN M AM SOC CLIN, P1498
[5]  
FLEMING GF, 2002, P AN M AM SOC CLIN, V21, pA202
[6]   Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study [J].
Hoskins, PJ ;
Swenerton, KD ;
Pike, JA ;
Wong, F ;
Lim, P ;
Acquino-Parsons, C ;
Lee, N .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (20) :4048-4053
[7]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[8]   Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study [J].
Lincoln, S ;
Blessing, JA ;
Lee, RB ;
Rocereto, TF .
GYNECOLOGIC ONCOLOGY, 2003, 88 (03) :277-281
[9]   A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study [J].
Miller, DS ;
Blessing, JA ;
Lentz, SS ;
Waggoner, SE .
GYNECOLOGIC ONCOLOGY, 2002, 87 (03) :247-251
[10]   Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group [J].
Moore, DH ;
Blessing, JA ;
Dunton, C ;
Buller, RE ;
Reid, GC .
GYNECOLOGIC ONCOLOGY, 1999, 75 (03) :473-475